Biography
Paul L Wood has completed his Ph.D. from Queen’s University and postdoctoral studies from the NIMH. He is the director of the Metabolomics Unit at Lincoln Memorial University and is professor of pharmacology and physiology. He has published more than 280 peer-reviewed papers.
Research Interest
The Metabolomics Unit utilizes high-resolution mass spectrometric analytical platforms to discover biomarkers of disease, of disease progression, and of diseases response to therapy. The metabolomics and lipidomics data obtained with these platforms also has to potential to define new therapeutic targets for drug development. Ongoing projects in the Metabolomics Unit include:
- Lipidomics of lung diseases
- Lipidomics of parasitic infections
- Lipidomics of fetal maturation
- Sperm lipidomics
- Lipidomics of Rodococcusequi
- Lipidomics and metabolomics of ovine paratuberculosis
- Lipidomics and metabolomics of leptospirosis
- Cancer lipidomics
- Lipidomics for postmortem interval determination
- Lipidomics and metabolomics of extracellular matrix degradation
Scientific Activities
Grant Review Committees and Advisory Committees
National High Magnetic Field Lab (FSU) External Advisory Committee: 2009-present
NIA: 2009-2010
Canada Foundation for Innovation: 2006-2007
ADMHA (Behavioral Neurobiology Subcommittee): 1987-1992
NIDA (Drug Abuse Biomedical Research Review Committee): 1987-1989
Grants
Mouse cuprizone model of demyelination. NSERC, 2008-2009 ($350,000). P. Wood, PI.
Novel therapeutics for chronic pain. SBIR (1R43NS51150-1) 2004-2006. ($150,000)
Agents for the treatment of memory and learning disorders. NIH 1992-1995. A Kozikowski, PI. ($569,024).
Operating Grant, Canadian MRC, 1983-1984 ($45,000) Cortical Opiate Receptors
Maintenance Grant, Canadian MRC, 1982-1984 ($30,000)
Operating Grant, Canadian MRC, 1981-193 (eith Dr. P. Etienne, $70,000) Neurochemical and Clinicopathological Studies of the Substantia Innominata and Septum in Alzheimer's Disease
Operating Grant, Canadian MRC, 1981-19831 ($70,000) Cortical and Hippocampal Cholinergic Pathways: Regulatory Inputs
Establishment Grant, Fonds de la Recherche en Sante du Quebec, 1981-1982 ($20,000)
DRUG DISCOVERY EXPERIENCE
- S-1A receptor agonists and S2 receptor antagonists
- Partial BZ agonists, inverse BZ agonists and BZ agonist/antagonist
- Neurosteroid agonists (Ganaxalone) Competitive (Selfotel) and non-competitive
- NMDA receptor antagonists
- NMDA-asociated glycine receptor agonists (Milacemide; D-cycloserine)
- NMDA-asociated glycine receptor antagonists (Licostinel)
- Anti-apoptosis compounds
- Atypical neuroleptics and DA autoreceptor agonists
- Tryptamine antagonist
- Adenosine agonists
- Kappa opiate agonists
- Enkephalinase inhibitors
- Sodium and calcium (Ziconotide) channel blockers
- Non-peptide BK-1 antagonists
- Inhibitors of MAPK activation
- NO donor / SOD mimetics
- Aldehyde trapping agents
- Plasmalogen precursors
DRUG DEVELOPMENT EXPERIENCE
Preclinical development (toxicology, ADME, safety pharmacology, CMC, DMF and formulation), Phase 1 and Phase 2 clinical trials.